The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
 
Syed N. Rahman
No Relationships to Disclose
 
Jessica B. Long
No Relationships to Disclose
 
Sarah J. Westvold
No Relationships to Disclose
 
Stephanie B. Wheeler
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Lisa P. Spees
No Relationships to Disclose
 
Michael Leapman
No Relationships to Disclose
 
Michael E. Hurwitz
Employment - Arvinas (I); Gamida Cell (I); Pfizer (I)
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; crispr therapeutics; Exelixis; Janssen; Nektar; pliant
Research Funding - Achilles Therapeutics; Apexigen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Endocyte; Endocyte; Genentech; Genmab; Innocrin Pharma; Iovance Biotherapeutics; Lilly; Merck; Nektar; Novartis; Novartis; Pfizer; Progenics; Sanofi/Aventis; Seagen; Torque; Unum Therapeutics
 
Hannah Dzimitrowicz McManus
Research Funding - Pfizer (Inst)
 
Cary Philip Gross
Research Funding - AstraZeneca (Inst); Genentech; Johnson & Johnson (Inst)
 
Michaela Ann Dinan
Research Funding - AstraZeneca (Inst); Janssen (I)